CLV IntelligenceReimbursement Policy Monitoring

Code intelligence

FDA-NDA213983 reimbursement alerts

Policy changes, MAC LCD updates, and CMS guidance matched to code FDA-NDA213983.

Elevated code risk

Signal breakdown

1 shown · 1 total in platform

Risk: Elevated
0

Critical

0%

1

High

100%

0

Routine

0%

0

Low

0%

New this month

+1

alerts added in last 30 days

Effective soon

—

no upcoming deadlines

FDA Approval: TIVICAY PD (DOLUTEGRAVIR SODIUM) — Type 3 - New Dosage Form

Policy FDA-NDA213983 · Infectious Disease

High

Tivicay PD (dolutegravir sodium) is an oral tablet for suspension approved as a new dosage form of the existing HIV integrase inhibitor dolutegravir, indicated for pediatric patients. As an oral formu

View alert

Audit documentation

Building an audit file that includes FDA-NDA213983?

The Tripwire Audit Pack exports 12 months of single-specialty policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.

See audit packs — $349One-time purchase · not a subscription